In Vitro Diagnostics (IVD)
Post-COVID, is the home testing boom sustainable?
A (Lab Director): Accuracy concerns persist. Home HPV tests have 20% false negative rates. Lab-based PCR with CLIA oversight is still the gold standard. We're seeing patients make treatment decisions based on faulty home results.
B (Diagnostics Entrepreneur): Consumers want convenience. Multiplex molecular tests (COVID + Flu + RSV + Strep at home) will be in every pharmacy by 2027. The technology (LAMP, CRISPR-based) is ready.
C (Regulatory - FDA): The new LDT rule gives us authority to regulate lab-developed tests. Many home-brew IVDs will be pulled from market unless they submit for 510(k) clearance. Expect enforcement in 2026.
D (Public Health): Access inequity persists. Medicaid doesn't reimburse home tests. Low-income patients rely on free clinic swabs. We need universal coverage for OTC IVDs, or we'll widen health disparities.